Literature DB >> 1588073

Metastatic bone disease of the pelvis and femur.

F H Sim.   

Abstract

Metastatic bone disease involving the pelvis and femur is a common clinical occurrence. A pathologic fracture in this region is a catastrophic event that results in significant pain and loss of function. Recent advances in surgical management of pathologic fractures, resulting in secure fracture stability or stable joint replacement, have allowed these patients to resume their pre-fracture level of activity and ambulation. The surgeon must be familiar with the various devices available, because the choice of surgical procedure depends on the location of the tumor. In selected patients with extensive destruction, methylmethacrylate can be used to enhance the security of fixation and stability. Moreover, a more aggressive approach to prophylactic fixation before a catastrophic fracture develops has distinct advantages.

Entities:  

Mesh:

Year:  1992        PMID: 1588073

Source DB:  PubMed          Journal:  Instr Course Lect        ISSN: 0065-6895


  4 in total

1.  The palliative role of orthopaedics.

Authors:  Wisam I Al-Hakim; Jacub M Jagiello; Ken Mannan; Tim W Briggs
Journal:  BMJ       Date:  2006-05-27

2.  The Carbofix™ "Piccolo Proximal femur nail": A new perspective for treating proximal femur lesion. A technique report.

Authors:  Carmine Zoccali; Antonella Soriani; Barbara Rossi; Nicola Salducca; Roberto Biagini
Journal:  J Orthop       Date:  2016-07-06

3.  Is There an Association Between Prophylactic Femur Stabilization and Survival in Patients with Metastatic Bone Disease?

Authors:  Travis C Philipp; Jacob D Mikula; Yee-Cheen Doung; Kenneth R Gundle
Journal:  Clin Orthop Relat Res       Date:  2020-03       Impact factor: 4.755

4.  Modified Unipolar Hemiarthroplasty for the Treatment of Metastatic Lesions of Proximal Femur with Pathological Fractures: Case Series of Six Patients.

Authors:  C Y Lim; S Mat-Hassan; M Awang; M F Md-Ariff; M A Hau-Abdullah
Journal:  Malays Orthop J       Date:  2019-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.